Final Dose Level Initiated in Ph 1 Trial of THE001
“After observing early signs of efficacy in our ongoing trial, this is another important milestone for our company, as it proves that THE001 can be administered safely,“ said Dr. Frank Hermann, CMO of Thermosome. “Of note, there were no signs of renal or cardiac impairment and no dedicated formulation-related adverse events such as infusion-related reactions due to the innovative liposomal formulation. No trial participant had to discontinue treatment due to adverse events. Together with the previously reported pharmacokinetic and anti-tumor activity data, the overall data from the trial look very encouraging as of now. They underline the great potential of THE001 plus regional hyperthermia in STS as a tolerable, innovative treatment modality that has significantly improved local clinical activity with non-inferior systemic exposure to doxorubicin, but with a favorable pharmacokinetic profile.“
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data